Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3701-3710

  O'Connor, Stephen J ^a   Barr, Kenneth J ^b   Wang, Le ^d   Sorensen, Bryan K ^d   Tasker, Andrew S ^c   Sham, Hing ^d   Shi Chung, Ng ^d   Cohen, Jerome ^d   Devine, Edward ^d   Cherian, Sajeev ^d   Saeed, Badr ^d   Zhang, Haichao ^d   Jang Yun, Lee ^d   Warner, Robert ^d   Tahir, Stephen ^d   Kovar, Peter ^d   Ewing, Patricia ^d   Alder, Jeffrey ^d   Mitten, Michael ^d   Leal, Juan ^d   Marsh, Kennan ^d   Bauch, Joy ^d   Hoffman, Daniel J ^d   Sebti, Said M ^e   Rosenberg, Saul H ^d   more..

^a BAYER CORPORATION   (United States)

^b Sunesis Pharmaceuticals Inc   (United States)

^c AMGEN INC   (United States)

^d ABBOTT LABORATORIES   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N BENZYL N 3 PYRIDYLAMINOMETHYL) 2 (2 METHYLPHENYL)BENZOYLMETHIONINE; 4 (N BENZYL N PHENYLAMINOMETHYL) 2 (2 METHYLPHENYL)BENZOYLMETHIONINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PANCREAS TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; BENZYLAMINES; ENZYME INHIBITORS; ETHERS; HUMANS; MICE; MICE, NUDE; NEUROPEPTIDES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0033539110     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9901935     Document Type: Article

References (32)

1. Barbacid, M. Ras Genes. Annu. Rev. Biochem. 1987, 56, 779.
2. Cox, A. D.; Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1997, 1333, F51-71.
3. Kiaria, H.; Spandidos, D. A. Mutations of ras Genes in Human Tumors (Review). Int. J. Oncol. 1995, 7, 413-421.
4. Bos, J. L. ras Oncogenes in Human Cancer: A Review. Cancer Res. 1989, 49, 4682-4689.
5. Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Chemotherapeutic. Cell 1994, 77, 175.
6. Gibbs, J. B.; Oliff, A. The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 143-166.
7. Singh, S. B.; Lingham, R. B. Farnesyl-Protein Transferase Inhibitors in Early Development. Exp. Opin. Invest. Drugs 1996, 5, 1589-1599.
8. Casey, P. J.; Solski, P. A.; Der, C. I.; Buss, J. E. p21 Ras is Modified by a Farnesyl Isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8223.
9. Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell. Biol. 1992, 4, 1008-1016.
10. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
11. Newman, C. M.; Magee, A. I. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim. Biophys. Acta 1993, 1155, 79-96.
12. Schafer, W. R.; Rine, J. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 1002, 26, 209-237.
13. deSolms, S. J.; Deana, A. A.; Giuliani, E. A.; Graham, S. L.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Scholtz, T. H.; Wiggins, J. M.; Gibbs, J. B.; Smith, R. L. Paeudopeptide Inhibitors of Protein Farnesyltransferase. J. Med. Chem. 1995, 38, 3967-3971.
14. deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Koblan, K. S.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Scholtz, T. H.; Wiscount, C. M.; Gibbs, J. B.; Smith, R. L. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase. J. Med. Chem. 1998, 41, 2651-2656.
15. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deanna, A. A.; Garsky, V. M.; Scholtz, T. H.; Gibbs, J. B.; Smith, R. L. Pseudopeptide Inhibitors of Ras Farnseyl-protein Transferase. J. Med. Chem. 1994, 37, 725.
16. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
17. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. T.; McDowell, R. S.; Crowley, C.; Lucas, B.; Levinson, A.; Marsters, J. C. Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells. Science 1993, 260, 1937.
18. Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein Farnesyltransferase Inhibitors Block the Growth of Ras-Dependant Tumors in Nude Mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141.
19. Leftheris, K.; Kline, T.; Vite, G. D.; Cho, Y. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weller, H. N.; Andahazy, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Developement of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity. J. Med. Chem. 1996, 39, 224-236.
20. Mallams, A. K.; Rossman, R. R.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K.; Petrin, J.; Wang, L.; Patton, R.; Bishop, W. R.; Carr, D. M.; Kirschmeier, P.; Catino, J. J.; Bryant, M. S.; Chen, K-J.; Korfmacher, W. A.; Nardo, C.; Wang, S.; Nomeir, A. A.; Lin, C.-C.; Li, Z. C. Inhibitors of Farnesyl Protein Transferase, 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. J. Med. Chem. 1998, 41, 877.
21. McNamara, D. J.; Leonard, D. M.; Shuler, K. R.; Kaltenbronn, J. S.; Quin, J., III; Bur, S.; Thomas, C. E.; Doherty, A. M.; Scholten, J. D.; Zimmerman, K K.; Gibbs, B. S.; Gowan, R. C.; Latash, M. P.; Leopold, W. R.; Przybranowaki, S. A.; Sebolt-Leopold, J. S. C-Terminal Modifications of Histidyl-N-benzylglycinamides To Give Improved Inhibition of Ras Farnesyltransferase, Cellular Activity, and Anticancer Activity in Mice. J. Med. Chem. 1997, 41.
22. Nagasu, T. Y.; Rowell, C.; Lewis, M. D.; Garcia, A. M. Inhibition of Human Tumor Xenograft Growth by Treatment with the Farnesyltransferase Inhibitor B956. Cancer Res. 1995, 55, 5310.
23. Njoroge, F. G.; Vibulbhan, B.; Rane, D. F.; Bishop, W. R.; Petrin, J.; Patton, R.; Bryant, M. S.; Chen, K.-J.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Structure-Activity Relationship of 3-Substituted N-(Pyridinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-6] pyridin-11-ylidene)-piperidine Inhibitors of Faraesy-Protein Transferase: Design and Synthesis of in Vivo Active Antitumor Compounds. J. Med. Chem. 1997, 40, 4290-4301.
24. Njoroge, F. G.; Taveras, A. G.; Kelly, J.; Remiszewski, S.; Mallams, A. K.; Wolin, R.; Afonso, A.; Cooper, A. B.; Rane, D. F.; Liu, Y. T.; Wong, J.; Vibulbhan, B.; Pinto, P.; Deskus, J.; Alvarez, C. S.; del Rosario, J.; Connolly, M.; Wang, J.; Desai, J.; Rossman, R. R.; Bishop, W. R.; Patton, R.; Wang, L.; Kirschmeier, P.; Bryant, M. S.; et al. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b] pyridin-11-(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor of Ras Farnesyltransferase: A New Therapeutic Target. J. Med. Chem. 1997, 40, 2971-2990.
25. Sebti, S. M.; Hamilton, A. D. New Approaches to Anticancer Drug Design Based on the Inhibition of Farnesyltransferase. DDT 1998, 3, 26-33.
26. (a) Augeri, D. J.; O'Connor, S. J.; Janowick, D.; Szczpankiewicz, B.; Sullivan, G.; Larsen, J.; Kalvin, D.; Cohen, J.; Devine, E.; Zhang, H.; Cherian, S.; Saeed, B.; Ng, S.-C.; Rosenberg, S. Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase. J. Med. Chem. 1998, 41, 4288-4300.
27. (b) Shen, W.; Fakhoury, S.; Donner, G.; Henry, K.; Lee, J. Y.; Zhang, H.; Cohen, J.; Warner, R.; Saeed, B.; Cherian, S.; Tahir, S.; Kovar, S.; Bauch, J.; Ng, S.-C.; Marsh, K; Sham, H.; Rosenberg, S. Potent Inhibitors of Protein Farnesyltransferase: Heteroarenes as Cysteine Replacements. Bioorg. Med. Chem. Lett. 1999, 9, 703-708.
28. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma With K-Ras Mutation and p53 Deletion. Cancer Res. 1995, 55, 4243-4247.
29. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors. J. Med. Chem. 1996, 39, 217-223.
30. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457.
31. 19 Portion of Amphidinolid-A. Tetrahedron Lett. 1989, 30.
32. Carlsson, L. A. F.; Helgstrand, A. J. E.; Stjernstrom, N. E. 5-Fluoro-3-Pyridinemethanol Esters Thereof and Therapeutically Acceptable Salts Thereof. Aktiebolaget Astra US 3,637,714, 1972.